Ventilator lung in newborns means damage to a baby’s lungs caused or worsened by mechanical breathing support. The ventilator can save life, but if pressures, volumes, or oxygen levels are too high or used too long, the tiny air sacs stretch, collapse and reopen, or get inflamed. This can lead to swelling, scarring, and long-term breathing problems known as BPD, especially in very premature babies. The goal is to give the least support needed and to wean early. PMC+2PMC+2 Four main injuries explain VILI: (1) Volutrauma (too much volume), (2) Barotrauma (too much pressure), (3) Atelectrauma (repeated collapse/reopening), and (4) Biotrauma (inflammation from mechanical stress). Preterm lungs are extra vulnerable because they have fewer, immature alveoli and less surfactant. This is why “gentle ventilation” and non-invasive support are preferred from the start. SpringerOpen+1
Ventilator lung in a newborn means injury to a baby’s lungs caused or worsened by breathing machines (ventilators) and high oxygen after birth. Very small or very sick babies sometimes cannot breathe well on their own. They need help from a machine that pushes air (and oxygen) into the lungs. This support can save a life, but if it is too strong, too long, or not well matched to the baby’s tiny lungs, it can stretch, squeeze, or irritate the lung tissue. This leads to swelling, tiny leaks, and scarring. Doctors call the short-term harm from the ventilator ventilator-induced lung injury (VILI). If the baby needs oxygen and support for a long time, and the lungs do not heal normally, the baby may develop a chronic lung condition called bronchopulmonary dysplasia (BPD). BPD means the baby still needs oxygen or breathing support many weeks after birth and may have breathing problems later in infancy and childhood. PMC+2PMC+2
Other names
Ventilator-induced lung injury (VILI) in neonates: the immediate injury from the ventilator itself. PMC+1
Ventilator-associated lung injury: a similar term; sometimes used interchangeably with VILI. PMC
Bronchopulmonary dysplasia (BPD) or chronic lung disease of prematurity: the long-term lung disease that can follow early injury and long oxygen/ventilator use. MSD Manuals
New BPD (Jensen definition): a modern way to grade BPD based on how much breathing support a baby still needs at 36 weeks post-menstrual age. PubMed+2PMC+2
Types
These are the main ways a ventilator can injure a newborn’s lungs. Think of them as types of stress the machine can put on tiny air sacs.
Volutrauma (too much volume)
The breaths are too big for the baby’s tiny lungs. Over-stretching tears delicate air sacs (alveoli) and triggers inflammation. Even a short time with too-large breaths can do harm in newborns. PMCBarotrauma (too much pressure)
The pressure used to push air in is too high. This can cause air leaks (like pneumothorax) and damage to the lung structure. PMCAtelectrauma (collapse and reopening)
If parts of the lung keep collapsing and popping open with each breath, the opening/closing cycle rubs and injures the lining. Proper end-expiratory pressure helps prevent this. PMCBiotrauma (inflammation from stress)
Stretch and pressure trigger the lung cells to release inflammatory signals. These chemicals can spread and make lung injury worse, and may affect other organs. PMCOxygen toxicity (hyperoxia injury)
Too much oxygen for too long forms reactive oxygen species that hurt cells. Tiny preterm lungs and antioxidant systems are very fragile, so careful oxygen targets matter. PMCShear injury from uneven lungs
When some areas are stiff and others are soft, air flows unevenly. The edges between open and closed regions feel the most “shear” and get injured first. PMCChronic remodeling leading to BPD
After early injury, the lung may heal with fewer, larger, simplified air sacs and small-airway scarring. This is the hallmark of modern BPD. PubMed
Causes and risk factors
Prematurity
The earlier a baby is born, the more fragile the lungs. Immature lungs are easily injured by pressure, stretch, and oxygen. MSD ManualsRespiratory distress syndrome (surfactant deficiency)
Without enough surfactant, the lungs are stiff and collapse easily, so higher pressures/volumes are needed—and injury risk rises. PMCHigh tidal volumes
Large breath sizes stretch the lung too far (volutrauma), especially harmful in tiny preterm infants. PMCHigh peak pressures
Excess pressure causes air leaks and tissue damage (barotrauma). PMCLow end-expiratory pressure (low PEEP)
Letting alveoli collapse between breaths causes repeated opening/closing (atelectrauma). PMCHigh oxygen levels for long periods
Oxygen is a drug. Too much for too long injures cells and increases later problems. PMCLong duration of ventilation
The longer a baby needs a ventilator, the more cumulative exposure to pressure, volume, and oxygen stress. MSD ManualsUneven (heterogeneous) lung disease
Areas of collapse next to over-inflated zones create stress at their borders, worsening injury. PMCRepeated intubations or difficult airways
More procedures can cause airway swelling, plugs, and instability, increasing ventilator needs and injury risk. MSD ManualsInfection or inflammation (before or after birth)
Chorioamnionitis and postnatal sepsis inflame the lungs and make them more sensitive to ventilator stress. MSD ManualsPatent ductus arteriosus (PDA) with over-circulation
Extra blood flow to the lungs can cause fluid buildup and need for higher support. MSD ManualsFluid overload and edema
Wet lungs are stiff and collapse easily, so higher ventilator settings are used, raising injury risk. MSD ManualsMeconium aspiration or pneumonia
Blocked or inflamed airways create uneven ventilation and more shear stress. PMCAir leaks (pneumothorax, interstitial emphysema)
These are both a result of and a contributor to further ventilator injury. PMCGenetic and developmental factors
Some infants have differences in lung growth or repair pathways that increase vulnerability. PubMedPoor nutrition
Babies who cannot grow well may not repair lung injury effectively, prolonging support. MSD ManualsPostnatal steroid exposure (timing/dose issues)
Steroids can help wean off the ventilator but have complex risks; suboptimal use can affect lung and overall outcomes. nejm.orgInadequate pain/sedation control
Struggling against the ventilator can lead to higher pressures/volumes and more injury. PMCSuboptimal ventilation mode or settings
Not using lung-protective strategies (like volume-targeted ventilation) increases VILI risk. Karger PublishersProlonged invasive ventilation instead of timely non-invasive support
Longer time with an endotracheal tube increases injury; gentle non-invasive support when possible can reduce risk. Karger Publishers
Symptoms and everyday signs
Fast breathing (tachypnea)
The baby breathes quickly to move enough air through injured lungs.Working hard to breathe
You may see chest retractions, flaring nostrils, or grunting—signs of effort.Needing extra oxygen
The baby’s oxygen level drops without support because the lungs exchange gases poorly.Blue lips or skin (cyanosis) during stress
When crying or feeding, oxygen needs rise and the baby may desaturate.Frequent oxygen “desaturation” alarms
The oxygen level dips, especially during handling or sleep.Pauses in breathing (apnea) or unstable breathing
Common in preterm infants and worsened by sick lungs.Coughing or wheeze (later)
Small-airway swelling and scarring can cause noisy breathing.Crackly breath sounds
Due to fluid, collapse, or scarring in small airways.Poor feeding tolerance
Breathing effort makes it hard to coordinate sucking and swallowing.Slow weight gain (poor growth)
Calories go to breathing effort and illness, not growth.Swelling (edema) in severe cases
Fluid overload or heart-lung strain can cause puffiness.Tiring quickly
The baby sleeps more, cries weakly, or cannot finish feeds.Frequent infections
Injured lungs clear mucus poorly and are vulnerable to germs.Longer hospital stay
Babies with BPD or ongoing VILI need more support and monitoring.Ongoing need for oxygen or breathing support at home
Some babies go home on oxygen; many improve over months as lungs grow.
(These signs are non-specific; doctors confirm the problem with tests and clinical criteria. MSD Manuals)
Diagnostic tests
(Grouped into Physical Exam, Manual Tests, Lab/Pathology, Electro-diagnostic, and Imaging)
A) Physical exam and bedside observation
Work-of-breathing check
The clinician watches for retractions, flaring, and grunting. These show how hard the baby must work to move air through stiff or swollen lungs.Breath sound exam (auscultation)
Listening with a stethoscope can reveal crackles (fluid/collapse) or wheezes (narrow airways). Asymmetry may suggest air leaks.Chest shape and movement
A “barrel” chest, paradoxical movement, or reduced expansion can hint at chronic changes like BPD.Oxygen-weaning trial at the bedside
Staff gently lower oxygen while watching the saturation monitor and baby’s comfort. If levels fall or effort rises, the lungs still need support. MSD ManualsGrowth and nutrition assessment
Weight gain, head growth, and length provide clues to lung recovery or ongoing disease, because poor lung function often limits growth. MSD Manuals
B) Manual clinical scoring and simple bedside maneuvers
Silverman-Anderson score
A simple 0–10 score using visible signs (retractions, grunting, etc.) to rate breathing difficulty in newborns. Higher scores suggest worse lung function.Downes score
Another bedside score combining respiratory rate, retractions, and breath sounds to grade distress.Gentle PEEP/CPAP response check
Clinicians observe how the baby responds to a bit more end-expiratory pressure. Improved oxygenation and less work can indicate collapse (atelectasis) that is recruitable.Spontaneous breathing or readiness-to-extubate trial
A short test with lower support to see if the baby can breathe comfortably on their own. Failure suggests persistent lung injury or weakness.Transillumination for suspected pneumothorax
In a dark room, a bright light on the chest can show a glowing side if free air is present—an air leak caused by barotrauma. Quick and bedside-ready.
C) Laboratory and pathology tests
Blood gas (arterial or capillary)
Measures oxygen (PaO₂), carbon dioxide (PaCO₂), and acidity (pH). Poor numbers despite support suggest worse lung function or ventilation-perfusion mismatch. MSD ManualsComplete blood count and inflammatory markers
White blood cells, C-reactive protein, or procalcitonin help detect infection, which can worsen ventilator injury or mimic it. MSD ManualsTracheal aspirate culture (if intubated)
A sample from the breathing tube checks for bacteria or viruses that may drive inflammation and higher ventilator needs. MSD ManualsElectrolytes and nutrition labs
Abnormal salt balance or poor protein levels can cause lung edema and slow recovery; correcting them supports healing.
D) Electro-diagnostic and physiologic monitoring
Continuous pulse oximetry
A light sensor on the skin shows oxygen saturation. Frequent desaturations suggest unstable lungs. Target ranges are chosen carefully to balance oxygen benefit and safety. PMCCapnography or transcutaneous CO₂ monitoring
Measures carbon dioxide levels breath-by-breath or through the skin. High CO₂ may mean inadequate ventilation; very low CO₂ can signal over-ventilation, which can also injure lungs. PMCRespiratory inductance plethysmography / polysomnography (selected cases)
Non-invasive bands around the chest/abdomen or sleep studies measure breathing pattern, pauses, and effort, helping evaluate apnea and the impact of lung disease.
E) Imaging and advanced lung assessment
Chest X-ray
Shows lung inflation, areas of collapse, air leaks, and—later—typical BPD patterns (patchy densities, over-inflation). Common, fast, and informative. MSD ManualsLung ultrasound
Bedside ultrasound can detect collapse (atelectasis), fluid, or pneumothorax without radiation. Helpful for frequent checks.CT or MRI (rare/special cases)
CT can detail anatomy and airways but involves radiation; MRI avoids radiation but is logistically harder in neonates. Used when answers are not clear from other tests.
Non-pharmacological treatments
Early CPAP instead of routine intubation
Using soft prongs or a mask to deliver continuous air pressure (CPAP) helps keep tiny air sacs open without a tube. Purpose: avoid intubation and lower mechanical stress. Mechanism: CPAP provides a small, steady pressure that prevents collapse and reduces the “open–close” injury, cutting the need for high breaths from a ventilator. It’s usually started right after birth in preterm babies with breathing trouble. MDPI+1Gentle invasive ventilation (low tidal volume)
If a tube is needed, clinicians choose small breaths, short inspiratory time, and avoid high pressures. Purpose: give lifesaving support while limiting stretch injury. Mechanism: low tidal volumes and careful pressure limits lessen volutrauma/barotrauma; frequent checks and blood gases guide fine-tuning. Frontiers+1Volume-targeted ventilation
The ventilator targets a set breath volume rather than just pressure. Purpose: stabilize each breath size to avoid over-inflation when lung compliance changes. Mechanism: automatic adjustments keep delivered volumes small and consistent, reducing injury swings. PMCHigh-frequency oscillatory ventilation (HFOV) in selected infants
HFOV gives very tiny breaths at very high rates. Purpose: maintain lung recruitment with minimal movement. Mechanism: tiny volume oscillations around a constant lung volume reduce collapse–reopen cycles, lowering atelectrauma in some situations. PMCPermissive hypercapnia (accepting slightly higher CO₂)
Teams sometimes accept mildly higher CO₂ levels if oxygen is safe. Purpose: avoid aggressive ventilation just to “normalize” numbers. Mechanism: smaller breaths and pressures reduce lung stretch; careful monitoring keeps pH acceptable. PMCOxygen targeting (avoid too high or too low)
Clinicians target safe oxygen saturation ranges to avoid both low oxygen and oxygen toxicity. Purpose: protect eyes and lungs while ensuring brain oxygenation. Mechanism: continuous pulse oximetry and alarms keep SpO₂ within a narrow, unit-defined range. PMCEarly surfactant with minimally invasive techniques (INSURE/LISA)
Some NICUs give surfactant through a thin catheter while the baby stays on CPAP. Purpose: treat surfactant deficiency without full ventilation. Mechanism: replacing missing surfactant reduces surface tension and improves lung stability, cutting collapse injury. FDA Access DataNon-invasive NIPPV (synchronized)
NIPPV adds gentle breaths over CPAP. Purpose: reduce work of breathing and failure of CPAP. Mechanism: synchronized puffs support weak breaths, keep alveoli open, and can prevent intubation. MDPIStrict infection-prevention bundles
Hand hygiene, tube-care checklists, and early extubation bundles lower infections. Purpose: prevent sepsis that worsens lung injury and lengthens ventilation. Mechanism: fewer infections mean less inflammation and fewer days on ventilators. PMCOptimal nutrition (human milk + fortification)
Preterm babies need high calories and protein for lung growth. Purpose: support lung repair and immune health. Mechanism: human milk reduces infections; fortifiers supply protein, minerals, and vitamins needed for alveolar growth. PMCCareful fluid management
Limiting extra fluid can reduce lung edema. Purpose: keep lungs dry enough to exchange oxygen well. Mechanism: daily weight, input–output, and targeted fluids reduce swelling and ventilation needs. PMCKangaroo care (skin-to-skin)
Placing the baby on the parent’s chest stabilizes breathing. Purpose: improve oxygenation, bonding, and growth. Mechanism: warmth and steady chest motion reduce stress hormones and oxygen needs. PMCPositioning (prone under monitoring)
Care teams may use prone positioning to improve oxygenation. Purpose: reduce work of breathing. Mechanism: better ventilation–perfusion match can decrease ventilator settings; always with monitors and NICU protocols. PMCEarly caffeine therapy (system strategy)
Although caffeine is a drug, many NICUs treat it as a system to avoid re-intubations. Purpose: prevent apnea, support extubation, and shorten ventilation. Mechanism: stimulates the breathing center and diaphragm strength, lowering ventilation exposure. PMCStandardized extubation/weaning protocols
Checklists and readiness tests encourage earlier, safer extubation. Purpose: reduce ventilation days. Mechanism: consistent criteria and post-extubation support (CPAP/NIPPV) limit re-intubations. FrontiersFamily-integrated care
Parents help with routine care and comfort. Purpose: reduce stress and improve growth and stability. Mechanism: calmer infants have steadier breathing and fewer desaturations. PMCAvoiding repeated intubation attempts
Use skilled staff and aids (video laryngoscopy as available). Purpose: limit airway trauma and inflammation. Mechanism: fewer attempts and shorter procedure times reduce lung and airway injury. PMCJudicious transfusions and anemia management
Preventing significant anemia supports breathing efficiency. Purpose: reduce oxygen/ventilation needs. Mechanism: better oxygen carrying capacity = less ventilator support. PMCUnit quality-improvement (QI) rounds on ventilation
Daily QI review of ventilator settings. Purpose: keep settings as low as safely possible. Mechanism: team attention to volumes/pressures reduces cumulative lung stress. PMCFollow-up programs after discharge
Special clinics track growth and breathing. Purpose: catch problems early and reduce re-hospitalization. Mechanism: coordinated care supports lung recovery and nutrition at home. AAP Publications
Drug treatments
(FDA labels cited from accessdata.fda.gov whenever applicable; many uses in preterm infants are off-label—clearly noted.
Caffeine citrate (CAFCIT®) — Methylxanthine
Dose/time (typical NICU): loading 20 mg/kg caffeine citrate, then 5–10 mg/kg/day; start early in very preterm infants. Purpose: treat apnea of prematurity, support extubation, and reduce time on ventilators. Mechanism: blocks adenosine receptors, stimulates the breathing center, improves diaphragm contractility, and may reduce inflammation. Side effects: tachycardia, irritability, feeding intolerance; monitor for NEC as with all preterms. FDA status: approved for apnea of prematurity; label provides dosing and safety. Its VILI/BPD reduction benefits are indirect by enabling earlier extubation. Use as part of a weaning plan. FDA Access Data+2FDA Access Data+2Poractant alfa (CUROSURF®) — Exogenous surfactant
Dose/time: intratracheal dosing per label for rescue treatment of RDS in preterm infants; given early when oxygen/CPAP fails. Purpose: improve lung stability, reduce pneumothorax, and allow lower ventilator settings. Mechanism: replaces deficient surfactant, lowers surface tension, keeps alveoli open, reducing atelectrauma. Side effects: transient oxygen/pressure changes, bradycardia; administer by experienced staff. FDA status: approved for RDS rescue; using less invasive administration (LISA) is practice-based (off-label technique), aimed at reducing VILI. FDA Access DataBeractant (SURVANTA®) — Exogenous surfactant
Dose/time: intratracheal per label for RDS. Purpose: same as poractant—stabilize alveoli and enable gentler ventilation. Mechanism: bovine-derived phospholipids with surfactant proteins reduce surface tension and collapse. Side effects: airway obstruction if not given correctly; transient oxygen swings. FDA status: approved for RDS; impact on VILI is indirect by lowering ventilator intensity. FDA Access DataHydrocortisone (SOLU-CORTEF®) — Systemic corticosteroid (off-label for BPD prevention/treatment)
Dose/time: unit-specific protocols (e.g., low-dose early hydrocortisone in extremely preterm infants at adrenal-insufficiency risk). Purpose: reduce lung inflammation and help extubation when oxygen/pressure needs remain high. Mechanism: glucocorticoid anti-inflammatory action decreases cytokines/edema. Side effects: hyperglycemia, hypertension, infection risk; dosing must be cautious. FDA label context: hydrocortisone injection label describes systemic effects and precautions; not specifically approved for BPD—this is off-label. FDA Access Data+1Dexamethasone — Systemic corticosteroid (off-label in BPD)
Dose/time: short, low-dose regimens late in NICU course to aid extubation. Purpose: reduce ventilator dependence in severe evolving BPD. Mechanism: potent glucocorticoid lowers lung inflammation and edema. Side effects: hyperglycemia, hypertension, possible neurodevelopmental concerns at high/prolonged doses; modern protocols use minimal doses. FDA label context: injection label lists systemic indications and warnings; BPD use is off-label and requires careful risk–benefit discussion. FDA Access Data+1Budesonide inhalation suspension (PULMICORT RESPULES®) — Inhaled corticosteroid (off-label in preterm BPD/evolving BPD)
Dose/time: nebulized doses vary in NICU studies; sometimes mixed intratracheally with surfactant in trials. Purpose: local anti-inflammatory effect to reduce oxygen/ventilator needs. Mechanism: corticosteroid action in airways reduces swelling and mucus. Side effects: oral thrush, adrenal suppression with prolonged/high doses; neonate use is off-label. FDA label context: approved for pediatric asthma; not labeled for preterm infants or BPD. FDA Access Data+1Furosemide injection — Loop diuretic (selective use)
Dose/time: intermittent small doses when pulmonary edema worsens oxygenation; neonate ototoxicity risk is higher—use sparingly. Purpose: dry the lungs to improve gas exchange and allow lower ventilator support. Mechanism: blocks sodium-potassium-chloride transporter in loop of Henle to remove fluid. Side effects: electrolyte loss, dehydration, ototoxicity (noted in neonates), nephrocalcinosis; careful monitoring required. FDA label context: labels warn about neonatal hearing loss risks and dosing cautions. FDA Access Data+1Chlorothiazide ± Spironolactone — Thiazide/aldosterone-antagonist diuretic combo (off-label)
Dose/time: chronic oral thiazide ± spironolactone can be used instead of furosemide in evolving BPD. Purpose: gentle long-term fluid control with fewer ototoxic risks. Mechanism: distal tubule sodium blockade (thiazide) plus potassium-sparing effect (spironolactone) to manage edema. Side effects: electrolyte shifts, hyponatremia/hyperkalemia; monitor labs. FDA label context: not labeled for BPD; infant use is off-label and protocol-based. FrontiersInhaled nitric oxide (INOmax®) — Pulmonary vasodilator
Dose/time: for term or near-term neonates with hypoxic respiratory failure and pulmonary hypertension; not for routine preterm BPD prevention. Purpose: improve oxygenation and lower pulmonary pressures when PH complicates ventilation. Mechanism: selective pulmonary vasodilation improves ventilation–perfusion matching. Side effects: rebound PH if stopped abruptly; methemoglobinemia with excess dosing. FDA label context: approved for term/near-term neonates with HRF/PH; careful weaning mandated. FDA Access Data+1Sildenafil (REVATIO®) — PDE-5 inhibitor (context: pediatric labeling varies with age)
Dose/time: used in older infants/children with pulmonary arterial hypertension; neonatal use is cautious/specialist-led. Purpose: treat BPD-associated pulmonary hypertension in selected patients. Mechanism: raises cGMP to relax pulmonary vessels, improving hemodynamics. Side effects: hypotension, GI upset, interaction with nitrates. FDA label context: the 2023 label contains pediatric PAH information; neonatal BPD-PH use remains specialist and often off-label. FDA Access DataAzithromycin — Macrolide antibiotic (off-label for Ureaplasma-associated lung inflammation)
Dose/time: short courses in research settings when infection suspected. Purpose: treat/eradicate organisms linked to inflammation that may worsen BPD risk. Mechanism: antibacterial plus immunomodulatory effects. Side effects: QT prolongation, liver dysfunction, pyloric stenosis risk signals in neonates are debated; use prudently. FDA label context: indications are for common infections; neonatal BPD prevention is off-label. FDA Access Data+1Vitamin A (retinol) — Fat-soluble vitamin (parenteral supplementation in VLBW)
Dose/time: unit protocols (e.g., 5,000 IU IM 3×/week for 4 weeks in classic trials). Purpose: lower BPD risk by improving epithelial integrity and surfactant function. Mechanism: supports lung growth and cell differentiation; deficiency is common in preterm infants. Side effects: injection discomfort, rare toxicity with excess. Evidence: Cochrane and subsequent reviews show modest BPD reduction with parenteral dosing; not an FDA-approved drug for BPD but widely studied. Cochrane+2cochranelibrary.com+2Albuterol (salbutamol) — Inhaled β₂-agonist (off-label in preterm BPD)
Dose/time: nebulized PRN for wheeze/bronchospasm in infants with evolving BPD. Purpose: relieve airway obstruction and improve airflow. Mechanism: relaxes airway smooth muscle via β₂ receptors. Side effects: tachycardia, tremor, hypokalemia; effect can be variable in BPD. FDA label context: approved for older pediatric asthma; neonatal BPD use is off-label. FrontiersIpratropium — Inhaled anticholinergic (off-label)
Dose/time: nebulized adjunct in obstructive physiology. Purpose: additional bronchodilation when β₂-agonist response is limited. Mechanism: blocks muscarinic receptors to reduce bronchoconstriction. Side effects: dry mouth, tachycardia. FDA label: approved for older age groups; BPD use is off-label. FrontiersSystemic antibiotics (e.g., ampicillin/gentamicin) for proven infection
Dose/time: culture-guided therapy only. Purpose: treat sepsis/pneumonia that increases ventilator needs and inflammation. Mechanism: pathogen-specific killing reduces lung inflammation load. Side effects: nephro/ototoxicity with aminoglycosides—dose by pharmacokinetics. FDA labels: standard neonatal dosing is label/guideline-based; always culture-directed. PMCPalivizumab (Synagis®) — RSV monoclonal antibody (prophylaxis after NICU)
Dose/time: monthly IM during RSV season for eligible infants (e.g., BPD, extreme prematurity). Purpose: prevent severe RSV that can cause rehospitalization and ventilator need. Mechanism: neutralizes RSV F protein to block infection. Side effects: injection-site reactions; anaphylaxis is rare. FDA label: indicated for prevention in high-risk infants including BPD. FDA Access DataAcetaminophen or ibuprofen for PDA closure (off-label/label varies by formulation)
Dose/time: NICU protocols treat significant PDA that worsens lung edema. Purpose: close PDA to improve lung mechanics and reduce ventilator needs. Mechanism: COX inhibition lowers prostaglandins, encouraging ductal closure. Side effects: renal/GI concerns—careful selection. FDA: ductal closure indications vary by product; practice often off-label. FrontiersSedation minimization (and careful analgesia)
Dose/time: only when clearly needed; prefer non-pharmacologic comfort first. Purpose: avoid over-sedation that prolongs ventilation. Mechanism: lighter sedation supports spontaneous breathing and earlier extubation. Side effects: drug-specific; always balance comfort and ventilator synchrony. Evidence: VILI prevention is supported by less exposure to injurious breaths. PMCDiuretic-sparing strategies (wean as able)
Dose/time: step-down plans limit chronic diuretics. Purpose: reduce side effects while keeping lungs dry enough for weaning. Mechanism: frequent reassessment prevents unnecessary exposure. Evidence: practice-based; aligns with minimizing iatrogenic harms in evolving BPD. FrontiersIndividualized pulmonary vasodilators under PH team
Dose/time: for infants with confirmed BPD-associated pulmonary hypertension, chosen by specialists (e.g., sildenafil later in infancy). Purpose: improve right-heart load and oxygenation. Mechanism: targeted vasodilation improves pulmonary hemodynamics. Side effects: drug specific; strict monitoring. Evidence/labels: see INO (term/near-term) and sildenafil pediatric labeling; neonatal BPD-PH beyond term is specialist, often off-label. FDA Access Data+1
Dietary molecular supplements
Vitamin A — Supports lung lining cells and surfactant; modestly lowers BPD when given parenterally. Dosing is protocol-based in VLBW infants (e.g., 5,000 IU IM 3×/week for 4 weeks in classic trials). Overuse can cause toxicity; only under NICU orders. Cochrane+1
Vitamin D — Helps immune function and bone growth; deficiency is common in preterm infants. Doses are tailored with labs; aim is normal levels, not “high dose.” Evidence for direct BPD reduction is mixed, but overall health support is clear. PMC
Human milk fortifier (protein, minerals) — Fortified human milk gives needed protein and micronutrients to grow lungs and muscles for breathing; dosing follows weight and labs. PMC
DHA/ARA (long-chain fatty acids) — May modulate inflammation and support lung/brain development; dosing follows NICU nutrition pathways. Evidence for BPD prevention is mixed; still used for overall development. PMC
Zinc — Important for growth and immunity; supplementing deficient infants improves weight gain, indirectly helping lung recovery; dose is lab-guided. PMC
Selenium — Antioxidant trace element; deficiency can worsen oxidative stress. Supplementation is careful and based on parenteral nutrition protocols. PMC
Iron — Supports red blood cells; prevents anemia that raises oxygen needs. Dosing is weight-based; monitor ferritin and hemoglobin. PMC
Carnitine — Aids energy metabolism; sometimes added in parenteral nutrition if low; evidence specific to BPD is limited. PMC
Choline — Component of surfactant phospholipids; provided via nutrition plans; targeted supplementation beyond standard care is investigational. PMC
Multivitamin (NICU formulation) — Ensures broad micronutrient coverage while growth is fast; exact composition and dose are protocol-based. PMC
Immunity-booster / regenerative / stem-cell drugs
Mesenchymal stem cells (MSC) — Experimental cell therapy to reduce lung inflammation/fibrosis in evolving BPD; dosing, route (intratracheal/IV), and safety are still under study. Not standard care. PMC
Erythropoietin (EPO) — neuro/anti-inflammatory potentials — Studied for neuroprotection and theoretical lung benefits; not approved for BPD; dosing varies by trial. PMC
IGF-1/IGFBP-3 — Investigational to support organ development in extreme prematurity; lung outcomes exploratory; specialist trials only. PMC
Budesonide mixed with surfactant (intratracheal) — Investigational approach delivering steroid directly with surfactant to reduce BPD; not FDA-approved for this use. FDA Access Data
Antioxidant strategies (e.g., N-acetylcysteine) — Studied to limit oxidative stress; no standard dosing for BPD; research only. PMC
Azithromycin for Ureaplasma-positive infants — Potential anti-inflammatory/antimicrobial benefit; dosing and benefit–risk remain under investigation; off-label. FDA Access Data
Procedures/surgeries
Tracheostomy — A breathing tube placed in the neck for infants who need very long ventilation. Why: improves comfort, allows growth and discharge planning, and can lower ventilator injury by enabling gentler settings and better airway care. PMC
PDA ligation/catheter closure — Surgical or catheter closure of a large patent ductus that causes lung flooding and ventilator dependence. Why: improves lung mechanics and oxygenation when medical therapy fails. PMC
Gastrostomy tube (± fundoplication) — Feeding tube (and anti-reflux surgery in select cases) for infants with severe BPD who cannot safely feed. Why: ensures nutrition and reduces aspiration that can worsen lung injury. PMC
ECMO (extracorporeal membrane oxygenation) — Heart-lung bypass for term/near-term infants with severe, reversible respiratory failure or PH. Why: buys time while lungs recover; used under strict criteria. FDA Access Data
Bronchoscopy with airway assessments — Looks for malacia, mucus plugs, or lesions. Why: treatable airway problems can reduce ventilator needs and injury. PMC
Preventions
Prevent prematurity and give antenatal steroids to eligible mothers. PMC
Use early CPAP and avoid routine intubation. MDPI
If intubated, use low tidal volumes and protective settings. Frontiers
Target oxygen carefully—avoid too high or too low. PMC
Early surfactant via minimally invasive technique when needed. FDA Access Data
Caffeine to support extubation. PMC
Infection bundles and strict hand hygiene. PMC
Human milk + fortification for growth. PMC
Careful fluids and edema control. PMC
Standardized weaning/extubation protocols and teamwork. Frontiers
When to see doctors urgently
Contact your clinician right away for fast breathing, chest pulling in, blue lips/skin, poor feeding, vomiting everything, fewer wet diapers, fever, unusual sleepiness, pauses in breathing, or any oxygen monitor alarms. These may signal breathing worsening, infection, or heart-lung strain and need prompt evaluation to prevent setbacks. AAP Publications
What to eat / what to avoid
What to eat: human milk (fortified if prescribed), high-calorie formula when ordered, adequate protein, vitamin/mineral supplements (A/D/iron/etc.) as the team prescribes, and frequent small feeds to reduce reflux and work of breathing. Avoid: unprescribed supplements, over-thickening agents unless ordered, smoke exposure, high-volume feeds that provoke reflux/aspiration, and any change to oxygen/feeding equipment without medical guidance. Good nutrition and avoiding smoke or infections help lungs heal and grow. PMC
FAQs
1) Is a ventilator always harmful?
No. It saves lives. Harm comes when pressures/volumes/oxygen are too high or used too long. Gentle strategies lower risk. PMC
2) Is VILI the same as BPD?
Related, but not the same. VILI is the immediate injury from the machine; BPD is the chronic lung disease that can follow. NCBI
3) Can we avoid intubation altogether?
Often, yes—by using CPAP/NIPPV and early surfactant through thin catheters. Some babies still need intubation. MDPI+1
4) What oxygen level is “safe”?
Units use narrow saturation targets to balance brain/eye safety with lung protection; alarms help stay in range. PMC
5) Does caffeine really help lungs?
Caffeine reduces apnea and helps earlier extubation, indirectly lowering VILI/BPD risk. PMC
6) Are steroids dangerous?
They carry risks. Low-dose, short courses—when a baby can’t be weaned—may help. Teams discuss risks/benefits with families. FDA Access Data+1
7) Do diuretics fix lung disease?
They only relieve fluid overload. Long use can cause side effects; clinicians prefer the lowest effective dose and duration. FDA Access Data
8) Is nitric oxide for all preemies?
No. INO is approved for term/near-term infants with PH and hypoxic failure, not routine preterm BPD prevention. FDA Access Data
9) What about sildenafil?
It’s used in pediatric PAH; in BPD-PH, use is specialist-guided and age-dependent; neonatal use is often off-label. FDA Access Data
10) Will vitamin A help?
Parenteral vitamin A in very low birth-weight infants modestly lowers BPD; dosing is protocol-based. Cochrane
11) Can infections worsen VILI?
Yes. Infections increase inflammation and ventilation time; prevention bundles are key. PMC
12) Do babies outgrow BPD?
Many improve over time as lungs grow, but some have long-term breathing issues; follow-up clinics are important. AAP Publications
13) Is bronchodilator therapy routine?
Not routine; used for documented obstruction or wheeze, with variable response. Frontiers
14) Are stem-cell treatments available?
Only in clinical trials; not standard of care. PMC
15) What can parents do every day?
Keep appointments, follow oxygen/feeding plans, avoid smoke/crowds during RSV season, and get recommended prophylaxis like palivizumab if eligible. FDA Access Data
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: November 03, 2025.
